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Numerous adverse effects follow anabolic agent abuse. Pulmonary hemorrhage is not considered one of
them. We present two cases of young male bodybuilders who developed diffuse alveolar bleeding as a
result of anabolic steroid abuse. Diffuse alveolar hemorrhage associated with anabolic agent abuse has
not been described previously in the literature. Both patients developed acute dyspnea and hemoptysis
with consistent radiological ﬁndings. In both cases symptoms promptly resolved with cessation of
exposure and no medical intervention was required and no signs of persistent lung damage were seen. It
is crucial to be aware of pulmonary hemorrhage as an acute complication of anabolic agent abuse. It
should be considered an important differential diagnosis in the athletic patient presenting with respi-
ratory symptoms.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Abuse of anabolic agents is associated with numerous adverse
effects including cardiac and thromboembolic complications [1,2]
cerebral hemorrhagic infarction [3,4] and intraabdominal hemor-
rhage [5e7]. Previously, the literature has not reported on pulmo-
nary hemorrhage related to anabolic steroids abuse. We report two
cases with young bodybuilders experiencing diffuse pulmonary
hemorrhage following anabolic steroids abuse.1.1. Case I
A 26-year old man presented in the emergency room with
malaise, dyspnea and hemoptysis. He had a history of intermittent
anabolic steroid abuse (AS) to enhance the results of his body-
building exercises. Six weeks prior to admission he had resumed
abuse, taking metandienone (60 mg p.o. daily), 57 testosterone
enanthate (1000 mg i.m. weekly), nandrolone (1 ampoule i.m.
weekly) and rapid-acting insulin (16I U s.c. daily). He denied any
other drug abuse and used no other types of medication. Prior to
admission he described ﬁve days with malaise, night sweats, dys-
pnea, cough and bloody sputum. Except for tachypnea and testic-
ular atrophy, the physical exam was normal. Routine laboratory
testing showed only marginally increased C-reactive protein, Aarhus C, Denmark.
d-Jensen).
Ltd. This is an open access article u(12.0 mg/l), leukocytes 13.0  109/l and creatinine 142 mmol/l.
Apart from a marginally elevated platelet count (378  109/l) and
International Normalized Ratio (INR) at 1.3 coagulation studies
were within normal limits. Troponin T was marginally elevated
(20 ng/l) but this normalised spontaneously within 4 h. The other
parameters, including arterial blood gases, were normal. Chest x-
ray showed left apical inﬁltration and basal atelectasis. An echo-
cardiography was performed showing slightly above-average right
and left ventricle size, normal ejection fraction and a slightly
elevated tricuspid regurgitation gradient of 27e30 mmHg, in-
dicates a marginally elevated pulmonary arterial pressure. High
resolution computed tomography (HRCT) showed areas of ground-
glass opacity in both lungs predominantly in peripheral regions;
this caused suspicion of diffuse alveolar hemorrhage (Fig. 1). The
patients was referred to our hospital 10 days later where a bron-
choscopy revealed no abnormal ﬁndings apart from increased
vascularisation of the bronchial mucosa. Microbiological and
pathological studies of the bronchoalveolar lavage (BAL) were
normal, including white blood cell differential and only few red
blood cells were detected. Additional blood tests showed normal
levels of immunoglobulin, a negative autoantibodies test and a
negative interferon gamma release assay (T-spot) were made. The
patient received no further medical treatment. Two and six months
following discharge a renewed HRCT showed complete disappear-
ance of the previously described ﬁndings. Lung function and
diffusion capacity for carbon monoxide were normal. He denied re-
exposure to AS since admission.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. HRCT showed patchy areas with ground glass opacities located primarily in the periphery of the lungs.
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A previously healthy 19-year-old man presented in the emer-
gency room with a two-week history of cough and increasing
dyspnea. The past two days he had experienced hemoptysis. He
reported a 3-year history of anabolic agent polydrug abuse. Two
weeks prior to admission, abuse had escalated; content consisted of
a mixture of oxymetholone (p.o.), methandriol (p.o.), trienolone
(i.m.) and nandrolone (i.m). Speciﬁc dosages could not be speciﬁed,
as the patient had no clear recollection. He took no medication,
including anticoagulants, and denied any additional abuse of drugs.
On admission he was tachypneic, otherwise the physical exami-
nation was normal. Laboratory tests showed marginally increased
C-reactive protein (14.0 mg/l). Other parameters, including leuco-
cytes and differential count were normal. D-dimer was slightly
elevated (0.72 mg/l FEU), additional coagulation studies were
within normal limits. Blood gasses demonstrated slight hypoxemia
(arterial PO2 9.6 kPa) with no hypercapnia (arterial PCO2 4.7 kPa).
Spirometry showed slightly reduced forced expiratory volume in 1
second (FEV1) of 3.38 L (74%) and forced vital capacity (FVC) of
4.53 L (83%). A heart ultrasonography was normal. A chest CT
showed large areas of patchy ground glass in the periphery of the
lung parenchyma consistent with diffuse alveolar bleeding (Fig. 2).
Bronchoscopy three days after admission revealed multiple small
blood clots in bilateral airways. The bronchoalveolar lavage ﬂuid
was bloody with 20% hemosiderin-containing macrophages. There
was no sign of infectious micro-organisms and the white blood cell
count was normal. Transbronchial lung biopsies revealed alveolar
tissue with diffuse bleeding and hemosiderin-laden macrophages.
Additional blood tests showed normal levels of immunoglobulin
and negative autoantibodies. He was diagnosed with drug-induced
alveolar hemorrhage. The patient was discharged without medi-
cation and two weeks later he reported disappearance of pulmo-
nary symptoms. Three and a half months following admission a
new HRCT showed disappearance of the previous ﬁndings.
Spirometry had normalised with FEV1 of 5.56 L (122%) and FVC of
6.74 L (124%). He no longer abused anabolic agents.
2. Discussion
Diffuse alveolar hemorrhage (DAH) is characterised by bleeding
into the alveolar spaces of the lungs due to disruption of thealveolar-capillary basement membrane. Clinical signs of the syn-
drome are dyspnea, hemoptysis, hypoxemic respiratory failure and
diffuse pulmonary inﬁltrates, but may be present in variable pro-
portions. DAH should be considered a potentially life-threatening
disorder due to the signiﬁcant morbidity and mortality [8]. Com-
mon conditions known to be associated with DAH include auto-
immune diseases (such as polyangiitis and granulomatosis
formerly known as Wegener's granulomatosis and Goodpasture
syndrome), sepsis and endocarditis [9]. The diagnosis is made by
bronchoscopy with BAL, laboratory tests, including coagulation
assays, platelet counts and , and a HRCT On HRCT alveolar hemor-
rhage is most often demonstrated as diffuse areas with ground
glass shadowing. Here, we report two cases of clinically relevant
diffuse alveolar hemorrhage associated with anabolic agent abuse.
While AS abuse is known to cause hemorrhage in other organs such
as the liver and brain [2,5], pulmonary hemorrhage due to AS abuse
has not previously been reported. In both cases the patients'
symptoms and HRCT ﬁndings promptly disappeared following
cessation of AS use. No medical intervention was needed and both
patients showed no signs of persistently reduced lung function. The
use of injectable compounds dissolved in oil or silicone has been
described to be associated in rare cases with systemic complica-
tions and acute respiratory distress [9,10]. Pathophysiology remains
unclear but is believed to be comparable with the mechanisms
involved in fat embolism syndrome (FES), involving a ventilation-
perfusion mismatch combined with local and systemic toxic and
inﬂammatory responses. Acute chest syndrome associated with
ﬂuid silicone, most often used for cosmetic purposes in transsexual
individuals, is known as the silicone embolism syndrome. Patients
develop amongst other chemical pneumonitis and alveolar hem-
orrhage. The clinical presentation varies but usually involves acute
onset of fever, dyspnea, tachycardia, hemoptysis and neurological
symptoms. In silicone embolism syndrome, the symptoms usually
present within the ﬁrst few hours following injection [10]. Radio-
logical ﬁndings typically reveal focal areas of consolidation and
ground glass predominantly in the peripheral and basilar regions.
There is one case report of a patient with oil-embolism syndrome
following accidental intravenous administration of an oil-steroid
solution [11]. This patient developed acute respiratory distress
and hypoxemia 24 hours after injection. In our two cases the pa-
tients reported abusing testosterone enanthate, an oil-based
injectable steroid solution. We were unable to detect the precise
Fig. 2. HRCT showed large areas with ground glass opacities in the periphery of the lung parenchyma.
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testosterone enanthate is vegetable oil, such as castor or sesame oil,
which can cause lung problems [12,13]. In both cases the patients'
symptoms slowly progressed over days/weeks and there was no
information about possible accidental intravenous administration
of the steroid solutions. Neither of the patients reported symptom
onset directly related to the time of injection. The symptomatology
of FES, silicone emboli syndrome and DAH is in many ways similar
and the radiological ﬁndings can be comparable but are not always
diagnostic. In the case of acute symptom onset and suspicion of
accidental intravenous administration of the steroid solution, pul-
monary embolism should be considered as a possible though rare
differential diagnosis. Due to the low incidence of symptomatic
events, radiological ﬁndings, bronchoalveolar lavage, clinical pre-
sentation and the patient's history can help make the diagnosis.
Although long-term effects of AS abuse such as myocardial hyper-
trophy and thromboembolic complications are known. Our cases
illustrate the importance of raising awareness of the. 180 acute and
possibly life-threatening adverse effects of anabolic steroid abuse.
In the case of HRCT, ﬁndings with predominantly ground glass
opacity primarily in the peripheral regions in an extremely athletic
patient, suspicion of anabolic agents induced DAH should be
considered. If DAH is suspected, bronchoscopy should be per-
formed immediately to establish. The diagnosis and withdrawal of
the suspected drug is crucial.
Conﬂicts of interest
None declared.References
[1] J.P. Higgins, A. Heshmat, C.L. Higgins, Androgen abuse and increased cardiac
risk, South Med. J. 105 (12) (2012) 670e674.
[2] M.C. Kennedy, A.B. Corrigan, S.T. Pilbeam, Myocardial infarction and cerebral
haemorrhage in a young body builder taking anabolic steroids, Aust. N. Z. J.
Med. 23 (6) (1993) 713.
[3] J. Moss-Newport, Anabolic steroid use and cerebellar haemorrhage, Med. J.
Aust. 158 (11) (1993) 794.
[4] Z. Shiozawa, S. Tsunoda, A. Noda, M. Saito, H. Yamada, Cerebral hemorrhagic
infarction associated with anabolic steroid therapy for hypoplastic anemia,
Angiology 37 (10) (1986) 725e730.
[5] N.M. Martin, B.K. Abu Dayyeh, R.T. Chung, Anabolic steroid abuse causing
recurrent hepatic adenomas and hemorrhage, World J. gastroenterol. 14 (28)
(2008) 4573e4575.
[6] S. Bagia, P.M. Hewitt, D.L. Morris, Anabolic steroid-induced hepatic adenomas
with spontaneous haemorrhage in a bodybuilder, Aust. N. Z. J. Surg. 70 (9)
(2000) 686e687.
[7] J. Schumacher, G. Muller, K.F. Klotz, Large hepatic hematoma and intra-
abdominal hemorrhage associated with abuse of anabolic steroids, N. Engl. J.
Med. 340 (14) (1999) 1123e1124.
[8] A. Parrot, M. Fartoukh, J. Cadranel, Alveolar hemorrhage, Rev. Mal. Respir. 32
(4) (2015) 394e412.
[9] R.J. Meyer, M. Mann, Pulmonary oil micro-embolism (POME) syndrome: a
review and summary of a large case series, Curr. Med. Res. Opin. 31 (4) (2015)
837e841.
[10] S. Bartsich, J.K. Wu, Silicon emboli syndrome: a sequela of clandestine liquid
silicone injections. A case report and review of the literature, J. plastic,
Reconstr. aesthet. Surg. JPRAS 63 (1) (2010) e1e3.
[11] M. Russell, A. Storck, M. Ainslie, Acute respiratory distress following intra-
venous injection of an oil-steroid solution, Can. Respir. J. 18 (4) (2011)
e59e61.
[12] J.R. Hain, Subcutaneous corn oil injections, fat embolization syndrome, and
death, Am. J. Forensic Med. Pathol. 30 (4) (2009) 398e402.
[13] H. Kiyokawa, K. Utsumi, K. Minemura, I. Kasuga, Y. Torii, M. Yonemaru, et al.,
Fat embolism syndrome caused by vegetable oil injection, Intern Med. 34 (5)
(1995) 380e383.
